REGN | Regeneron Pharmaceuticals, Inc. | [NASD]
IndexNDX, S&P 500 P/E19.80 EPS (ttm)36.80 Insider Own0.50% Shs Outstand107.10M Perf Week-3.05%
Market Cap79.93B Forward P/E16.79 EPS next Y43.38 Insider Trans-8.55% Shs Float104.32M Perf Month-9.13%
Income4.18B PEG7.07 EPS next Q10.19 Inst Own89.50% Short Float / Ratio1.16% / 2.11 Perf Quarter-4.18%
Sales12.37B P/S6.46 EPS this Y-46.90% Inst Trans-0.34% Short Interest1.21M Perf Half Y-1.04%
Book/sh219.38 P/B3.32 EPS next Y4.32% ROA14.70% Target Price889.32 Perf Year6.61%
Cash/sh81.67 P/C8.92 EPS next 5Y2.80% ROE19.00% 52W Range538.01 - 837.55 Perf YTD0.99%
Dividend- P/FCF31.63 EPS past 5Y23.80% ROI16.60% 52W High-13.01% Beta0.24
Dividend %- Quick Ratio4.70 Sales past 5Y15.70% Gross Margin87.00% 52W Low35.42% ATR14.40
Employees11851 Current Ratio5.50 Sales Q/Q6.60% Oper. Margin35.80% RSI (14)34.61 Volatility1.52% 1.84%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.70% Profit Margin33.80% Rel Volume0.86 Prev Close725.05
ShortableYes LT Debt/Eq0.11 EarningsMay 04 BMO Payout0.00% Avg Volume575.84K Price728.60
Recom2.10 SMA20-3.55% SMA50-7.23% SMA200-1.04% Volume497,087 Change0.49%
Date Action Analyst Rating Change Price Target Change
Mar-27-23Upgrade SVB Securities Market Perform → Outperform $834 → $976
Mar-24-23Upgrade Jefferies Hold → Buy $675 → $925
Mar-23-23Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23Upgrade Cowen Market Perform → Outperform $775 → $875
Jan-20-23Upgrade JP Morgan Neutral → Overweight $850
Oct-26-22Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22Downgrade Evercore ISI Outperform → In-line $760
Sep-09-22Upgrade Morgan Stanley Equal-Weight → Overweight $625 → $851
Sep-09-22Upgrade Jefferies Underperform → Hold $536 → $675
Jul-25-22Downgrade SVB Leerink Outperform → Mkt Perform $630
May-26-23 11:04AM
May-25-23 05:05PM
May-22-23 01:50PM
02:18PM Loading…
May-21-23 02:18PM
May-20-23 07:01AM
May-19-23 03:32PM
May-18-23 04:01PM
May-17-23 12:01AM
09:00AM Loading…
May-16-23 09:00AM
May-15-23 03:59PM
May-10-23 09:53AM
May-09-23 11:33PM
May-05-23 05:17PM
May-04-23 11:18PM
08:50AM Loading…
May-03-23 11:46AM
May-02-23 11:40AM
May-01-23 08:02AM
Apr-28-23 01:12PM
Apr-27-23 06:15PM
Apr-26-23 04:05PM
Apr-24-23 01:34PM
Apr-21-23 06:15PM
Apr-20-23 01:07PM
Apr-18-23 10:00AM
Apr-17-23 09:50AM
Apr-14-23 10:00AM
Apr-11-23 04:00PM
Apr-09-23 09:30AM
Apr-08-23 07:00AM
Apr-07-23 12:10PM
Apr-06-23 05:39AM
Apr-04-23 09:00AM
Apr-03-23 04:00PM
Mar-31-23 10:15PM
Mar-29-23 11:24AM
Mar-28-23 03:25PM
Mar-27-23 06:51PM
Mar-26-23 08:45AM
Mar-25-23 12:54PM
Mar-24-23 02:29PM
Mar-23-23 04:40PM
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN ARTHUR FDirectorMay 01Sale805.3310080,53318,947May 03 04:01 PM
BROWN MICHAEL SDirectorApr 21Option Exercise520.013,0701,596,4314,317Apr 24 04:05 PM
BROWN MICHAEL SDirectorApr 21Sale798.423,0702,451,1491,247Apr 24 04:05 PM
McCourt MarionEVP CommercialApr 03Option Exercise372.461,100409,70621,903Apr 05 04:00 PM
McCourt MarionEVP CommercialApr 03Sale818.801,100900,68020,803Apr 05 04:00 PM
RYAN ARTHUR FDirectorApr 03Sale819.3110081,93119,047Apr 05 04:01 PM
Landry Robert EEVP Finance CFOMar 28Sale823.471,007829,23331,922Mar 29 04:07 PM
Landry Robert EEVP Finance CFOMar 27Option Exercise379.603,8001,442,47635,316Mar 29 04:07 PM
Landry Robert EEVP Finance CFOMar 27Sale821.70183150,37232,929Mar 29 04:07 PM
Bassler Bonnie LDirectorMar 24Option Exercise380.951,240472,3782,487Mar 27 04:43 PM
Bassler Bonnie LDirectorMar 24Sale818.001,2401,014,3201,247Mar 27 04:43 PM
LAROSA JOSEPH JEVP General Counsel and SecretMar 23Option Exercise270.4310,0002,704,30034,213Mar 27 04:39 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 23Sale804.263,6562,940,374196,848Mar 27 04:41 PM
Fenimore Christopher R.SVP ControllerMar 23Sale806.472,1921,767,78218,409Mar 27 04:37 PM
McCourt MarionEVP CommercialMar 01Option Exercise372.461,100409,70621,903Mar 03 04:03 PM
McCourt MarionEVP CommercialMar 01Sale759.891,100835,87920,803Mar 03 04:03 PM
RYAN ARTHUR FDirectorMar 01Sale762.5010076,25019,147Mar 03 04:03 PM
VAGELOS P ROYDirectorFeb 22Option Exercise270.4342,50011,493,275366,583Feb 24 04:07 PM
McCourt MarionEVP CommercialFeb 07Option Exercise372.461,000372,46023,079Feb 08 04:14 PM
McCourt MarionEVP CommercialFeb 07Sale769.041,000769,04022,079Feb 08 04:14 PM
GOLDSTEIN JOSEPH LDirectorFeb 06Option Exercise482.683,6131,743,9239,860Feb 08 04:16 PM
BROWN MICHAEL SDirectorFeb 06Option Exercise520.013,0711,596,9514,318Feb 08 04:15 PM
YANCOPOULOS GEORGEPresident and Chief ScientificFeb 06Sale800.0813,18910,552,255200,504Feb 08 04:15 PM
GOLDSTEIN JOSEPH LDirectorFeb 06Sale800.003,6132,890,4006,247Feb 08 04:16 PM
BROWN MICHAEL SDirectorFeb 06Sale798.003,0712,450,6581,247Feb 08 04:15 PM
Landry Robert EEVP Finance CFOFeb 06Sale788.88752593,23832,105Feb 07 04:09 PM
BROWN MICHAEL SDirectorFeb 06Sale797.00500398,5006,162Feb 08 04:15 PM
Fenimore Christopher R.SVP ControllerFeb 03Option Exercise270.435,0001,352,15023,581Feb 07 04:10 PM
Landry Robert EEVP Finance CFOFeb 03Option Exercise381.923,0001,145,76035,105Feb 07 04:09 PM
Bassler Bonnie LDirectorFeb 03Option Exercise380.951,021388,9502,268Feb 07 04:09 PM
Bassler Bonnie LDirectorFeb 03Sale779.001,021795,3591,247Feb 07 04:09 PM
Landry Robert EEVP Finance CFOFeb 03Sale764.50739564,96632,105Feb 07 04:09 PM
McCourt MarionEVP CommercialFeb 01Option Exercise372.461,100409,70623,179Feb 03 04:13 PM
McCourt MarionEVP CommercialFeb 01Sale752.191,100827,40922,079Feb 03 04:13 PM
RYAN ARTHUR FDirectorFeb 01Sale756.1310075,61319,247Feb 03 04:15 PM
BROWN MICHAEL SDirectorJan 27Option Exercise520.0115201,248Jan 30 04:11 PM
BROWN MICHAEL SDirectorJan 27Sale747.0017471,247Jan 30 04:11 PM
BROWN MICHAEL SDirectorJan 06Option Exercise520.013,0701,596,4314,317Jan 10 04:03 PM
BROWN MICHAEL SDirectorJan 06Sale747.143,0702,293,7201,247Jan 10 04:03 PM
McCourt MarionEVP CommercialJan 03Option Exercise372.461,100409,70623,179Jan 05 04:22 PM
McCourt MarionEVP CommercialJan 03Sale721.861,100794,04622,079Jan 05 04:22 PM
RYAN ARTHUR FDirectorJan 03Sale726.2910072,62919,182Jan 05 04:37 PM
COLES N ANTHONYDirectorDec 28Option Exercise442.245,7582,546,4106,851Dec 30 04:10 PM
COLES N ANTHONYDirectorDec 28Sale714.115,7584,111,8221,093Dec 30 04:10 PM
McCourt MarionEVP CommercialDec 12Sale730.17264192,76519,106Dec 13 04:13 PM
Landry Robert EEVP Finance CFODec 08Option Exercise381.923,0001,145,76031,744Dec 12 04:34 PM
Bassler Bonnie LDirectorDec 08Option Exercise380.9521883,0471,300Dec 12 04:35 PM
Bassler Bonnie LDirectorDec 08Sale779.00218169,8221,082Dec 12 04:35 PM
Landry Robert EEVP Finance CFODec 02Sale756.66610461,56428,744Dec 02 04:05 PM
Landry Robert EEVP Finance CFODec 01Option Exercise381.922,500954,80031,244Dec 02 04:05 PM
McCourt MarionEVP CommercialDec 01Option Exercise372.461,100409,70620,744Dec 02 04:06 PM
McCourt MarionEVP CommercialDec 01Sale756.191,100831,80919,644Dec 02 04:06 PM
RYAN ARTHUR FDirectorDec 01Sale758.1710075,81719,282Dec 02 04:07 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 23Sale740.7511,9728,868,26030,578Nov 25 01:07 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 22Option Exercise378.9850,00018,949,00080,578Nov 25 01:07 PM
MURPHY ANDREW JEVP ResearchNov 15Sale727.813,7202,707,46757,110Nov 16 04:01 PM
MURPHY ANDREW JEVP ResearchNov 14Option Exercise179.1310,0001,791,30067,110Nov 16 04:01 PM
BROWN MICHAEL SDirectorNov 08Option Exercise416.623,9951,664,3973,513Nov 10 04:00 PM
BROWN MICHAEL SDirectorNov 08Sale755.183,9953,016,9461,082Nov 10 04:00 PM
BROWN MICHAEL SDirectorNov 08Sale748.49500374,2456,662Nov 10 04:00 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 07Sale745.407,8865,878,26330,578Nov 08 04:00 PM
Van Plew Daniel PEVP & General Mgr, IndustrialNov 04Option Exercise381.9234,00012,985,28064,578Nov 08 04:00 PM
McCourt MarionEVP CommercialNov 04Option Exercise372.461,000372,46020,644Nov 07 04:05 PM
McCourt MarionEVP CommercialNov 04Sale727.821,000727,82019,644Nov 07 04:05 PM
McCourt MarionEVP CommercialNov 01Option Exercise372.461,100409,70620,744Nov 02 04:03 PM
McCourt MarionEVP CommercialNov 01Sale750.001,100825,00019,644Nov 02 04:03 PM
Landry Robert EEVP Finance CFONov 01Sale758.06482365,38628,744Nov 02 04:04 PM
RYAN ARTHUR FDirectorNov 01Sale755.8910075,58919,382Nov 03 04:03 PM
Landry Robert EEVP Finance CFOOct 31Option Exercise381.922,000763,84030,744Nov 02 04:04 PM
Landry Robert EEVP Finance CFOOct 17Sale739.50358264,74128,744Oct 18 04:06 PM
Landry Robert EEVP Finance CFOOct 14Option Exercise381.921,500572,88030,244Oct 18 04:06 PM
Fenimore Christopher R.SVP ControllerOct 05Sale749.001,8441,381,15616,425Oct 07 04:03 PM
Tessier-Lavigne MarcDirectorOct 03Option Exercise413.333,6121,492,9485,881Oct 03 04:05 PM
McCourt MarionEVP CommercialOct 03Option Exercise359.041,100394,94120,244Oct 05 04:11 PM
Tessier-Lavigne MarcDirectorOct 03Sale718.003,6122,593,4162,269Oct 03 04:05 PM
Fenimore Christopher R.SVP ControllerOct 03Sale724.003,3462,422,50418,269Oct 05 04:10 PM
McCourt MarionEVP CommercialOct 03Sale705.391,100775,92919,644Oct 05 04:11 PM
RYAN ARTHUR FDirectorOct 03Sale726.5410072,65419,482Oct 05 04:10 PM
Tessier-Lavigne MarcDirectorSep 30Option Exercise413.333,4281,416,8955,697Oct 03 04:05 PM
Tessier-Lavigne MarcDirectorSep 30Sale698.003,4282,392,7442,269Oct 03 04:05 PM
Tessier-Lavigne MarcDirectorSep 29Option Exercise413.333,7981,569,8276,067Oct 03 04:05 PM
Tessier-Lavigne MarcDirectorSep 29Sale691.073,7982,624,6842,269Oct 03 04:05 PM
Van Plew Daniel PEVP & General Mgr, IndustrialSep 12Sale716.384,6963,364,11130,578Sep 13 04:04 PM
Van Plew Daniel PEVP & General Mgr, IndustrialSep 09Option Exercise555.6740,00022,226,80070,578Sep 13 04:04 PM
LAROSA JOSEPH JEVP General Counsel and SecretSep 09Option Exercise270.4330,0008,112,90041,580Sep 12 04:30 PM
Bassler Bonnie LDirectorSep 09Option Exercise376.69609229,4041,691Sep 12 04:31 PM
Bassler Bonnie LDirectorSep 09Sale741.00609451,2691,082Sep 12 04:31 PM
Bassler Bonnie LDirectorSep 08Option Exercise391.922,5581,002,5312,361Sep 12 04:31 PM
Bassler Bonnie LDirectorSep 08Sale696.002,5581,780,3551,082Sep 12 04:31 PM
COLES N ANTHONYDirectorSep 06Option Exercise372.406,0002,234,4286,793Sep 08 04:06 PM
COLES N ANTHONYDirectorSep 06Sale581.286,0003,487,6571,093Sep 08 04:06 PM
RYAN ARTHUR FDirectorSep 06Sale582.3710058,23719,582Sep 08 04:07 PM
McCourt MarionEVP CommercialSep 01Option Exercise342.931,100377,22320,744Sep 02 04:07 PM
McCourt MarionEVP CommercialSep 01Sale577.621,100635,38219,644Sep 02 04:07 PM
MURPHY ANDREW JEVP ResearchAug 16Sale645.493,5132,267,60058,470Aug 17 04:04 PM
MURPHY ANDREW JEVP ResearchAug 15Option Exercise179.1310,0001,791,30068,470Aug 17 04:04 PM
POON CHRISTINE ADirectorAug 09Option Exercise177.8215,0002,667,30016,872Aug 11 04:09 PM
POON CHRISTINE ADirectorAug 09Sale620.9115,0009,313,5991,872Aug 11 04:09 PM
STAHL NEILEVP Research and DevelopmentAug 05Sale612.6123,78214,569,13452,795Aug 08 04:11 PM
STAHL NEILEVP Research and DevelopmentAug 04Option Exercise270.4395,00025,690,850147,795Aug 08 04:11 PM